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Abstract 
Rationale 
MDPV (3,4-methylenedioxypyrovalerone) is a synthetic cathinone present in bath salts. 
It is powerful psychostimulant and blocker of the dopamine transporter (DAT), like 
cocaine. It is known that acute exposure to psychostimulants induces rapid changes in 
DAT function. 
Objectives 
To investigate the effects of MDPV on DAT function comparing with cocaine . 
Methods 
Binding of [3H]WIN 35428 was performed on PC 12 cells treated with MDPV and 
washed. Rat striatal synaptosomes were incubated with MDPV or cocaine (1 µM) for 1 
h and [3H]dopamine (DA) uptake was performed. Also, different treatments with 
MDPV or cocaine were performed in Sprague-Dawley rats to assess locomotor activity 
and ex vivo [3H]DA uptake.  
Results 
MDPV increased surface [3H]WIN 35428 binding on PC 12 cells. In vitro incubation of 
synaptosomes with MDPV produced significant increases in Vmax and KM for [
3H]DA 
uptake. In synaptosomes from MDPV- (1.5 mg/kg, s.c.) and cocaine- (30 mg/kg, i.p.) 
treated rats there was a significantly higher and more persistent increase in [3H]DA 
uptake in the case of MDPV than cocaine. Repeated doses of MDPV developed 
tolerance to this DAT upregulation and 24 h after the 5-day treatment with MDPV, 
[3H]DA uptake was reduced. However, a challenge with the same drugs after 
withdrawal recovered the DAT up-regulation by both drugs and showed an increased 
response to MDPV vs the first dose. At the same time, animals were sensitized to the 
stereotypies induced by both psychostimulants. 
Conclusions 
MDPV induces a rapid and reversible functional up-regulation of DAT more powerfully 
and lasting than cocaine.  
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
3 
 
Keywords: bath salts, cathinones, cocaine, dopamine transporter, dopamine uptake, 
MDPV, up-regulation.  
Introduction 
Membrane neurotransmitter transporters play a key role in the regulation of neural 
transmission as they are responsible for removal of neurotransmitters released into the 
synaptic cleft upon neuronal stimulation. Thus, the dopamine transporter (DAT) is 
crucial for dopaminergic transmission in the nigrostriatal and mesocorticolimbic 
dopaminergic pathways (see Lohr et al. 2017 or Torres et al. 2013 as reviews) and 
modifications in its density or transport rate can reduce or enhance the effects of a given 
amount of dopamine (DA). 
DAT, as other monoamine transporters, exhibits a great ability to modify its density in 
the plasma membrane through a very fast trafficking through internalization and 
recycling in a protein kinase C (PKC)-regulated manner (Loder and Melikian 2003; 
Ramamoorthy et al. 2011; Schmitt and Reith 2010). 
Psychostimulants increase synaptic monoamine levels by acting on their transporters, 
either by directly binding and inhibiting their function (e.g., cocaine, Ritz et al. 1987) or 
through a combined mechanism consisting in entering the cell as a transporter substrate 
and reversing the transport of cytosolic monoamines (e.g., amphetamine) which are 
previously displaced from synaptic vesicles by the drug (Sulzer and Galli 2003).  
Apart from these acute effects on monoamine uptake, rapid and reversible 
compensatory changes in transporters and their function have been reported as well. . 
Generally speaking, using samples from which residual drug has been washed away, 
psychostimulants that act as substrates of the transporters (e.g., amphetamine and 
analogues) induce an acute decrease in uptake, whereas blockers (e.g., cocaine or 
methylphenidate) tend to increase it. For example, an acute injection of 
methamphetamine (METH) to rats reversibly decreases plasmalemmal DA uptake in 
striatal synaptosomes (Fleckenstein et al. 1997). Similarly, uptake of serotonin is 
affected by METH treatment (Haughey et al. 2000). Moreover, in vitro incubation of 
striatal synaptosomes with METH followed by drug washout, rapidly decreased DAT 
activity, but not total WIN 35428 binding sites (Escubedo et al. 2005; Pubill et al. 2005; 
Sandoval et al. 2001). Similar effects were reported for MDMA (3,4-
methylenedioxymethamphetamine) (Chipana et al. 2006; Hansen et al. 2002). It has 
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been reported that PKC-mediated DAT phosphorylation contributes to this in vitro 
amphetamines-induced deficit (Cervinski et al. 2005; Giambalvo 2003; Sandoval et al. 
2001) which is accompanied by transporter internalization (Saunders et al. 2000; 
Johnson et al. 2005). 
Regarding cocaine, published results from animal in vivo and human post-mortem 
studies are variable depending on the subjects and experimental design. Most reports 
demonstrate that chronic exposure to cocaine increases DAT binding sites and function 
(Little et al. 1999; Mash et al. 2002; Staley et al. 1994), but others show a decrease or 
no change in the striatum following cocaine exposure (i.e Farfel et al. 1992; Izenwasser 
and Cox 1990; Letchworth et al. 1997; Peraile et al. 2010; Samuvel et al. 2008; Wilson 
et al. 1994). However, in vitro studies in hDAT-transfected cells generally report that 
acute cocaine treatment produces increases in surface [3H]WIN 35428 binding and 
[3H]DA uptake, with no change in DAT total protein or mRNA, but through induction 
of the trafficking from endosomes to the plasma membrane by a mechanism that 
remains to be elucidated (Little et al. 2002; Zahniser and Sorkin 2009).   
Synthetic cathinones have become a very popular group of illicit psychostimulants as 
substitutes of other amphetamine derivatives such as methamphetamine or MDMA 
(Drug Facts 2018:  https://www.drugabuse.gov/publications/drugfacts/synthetic-
cathinones-bath-salts). One such synthetic cathinone, MDPV (3,4-
methylenedioxypyrovalerone), shares pharmacodynamics with cocaine. It is a common 
ingredient of the so-called bath salts (Zuba and Byrska 2013; Johnson and Johnson 
2014), which are commercialized by certain Internet sites, although it is currently 
banned in many countries because its consumption has led to several life-threatening 
medical consequences (Kesha et al. 2013; Wright et al. 2013). It is a highly selective 
and potent reuptake inhibitor at monoamine transporters, with greater specificity for the 
DAT and norepinephrine transporters, compared to that for serotonin transporters. In 
vitro experiments have shown that MDPV is a more potent reuptake inhibitor than 
cocaine at DAT (Baumann et al. 2013; Cameron et al. 2013; Simmler et al. 2013), while 
in vivo studies have found that MDPV has is at least 10-fold more potent at increasing 
extracellular DA than cocaine (Baumann et al. 2013). Moreover, MDPV robustly 
increases locomotion, traveled distance and stereotypic movements in rats and mice and 
produces more intense locomotor and rewarding effects compared to cocaine (Aarde et 
al. 2013; Gatch et al. 2013; Lopez-Arnau et al. 2017).  
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Considering the persistence of synthetic cathinone abuse, especially MDPV (Alvarez et 
al. 2017; Bade et al. 2017), it is necessary to increase the knowledge of its 
neuropharmacological profile to better understand the effects and risks of this drug. To 
our knowledge, there are no previous reports of the effects of MDPV or any other 
synthetic cathinone on DAT regulation. Therefore, the aim of this work is to investigate 
the effects of MDPV on DAT density and function, using in vitro (PC12 cells and 
striatal synaptosomes) and ex vivo models (striatal synaptosomes from treated rats) after 
an acute exposure to the drug and a sensitization regime. Parallel experiments with 
cocaine were also run in order to compare their effects 
Materials and methods 
Drugs and reagents 
MDPV was synthesized in racemic form as hydrochloride in our laboratory as described 
previously (Novellas et al. 2015) and with permission from the University of Barcelona. 
Cocaine-HCl was provided by the Spanish National Institute of Toxicology. MDPV and 
cocaine solutions for injection were freshly prepared in saline (0.9 % NaCl, pH = 7.4) 
every day before administration. 
[3H]DA and [3H]WIN 35428 were from PerkinElmer (Boston, MA, USA). Dulbecco’s 
modified Eagle’s medium (DMEM), culture serums and antibiotics were purchased 
from GIBCO (Invitrogen Corp., Paisley, UK). Pargyline, bupropion, HEPES sodium 
and ascorbic acid were purchased from Sigma-Aldrich Company Ltd. All other reagents 
were of analytical grade and obtained from several commercial sources.  
PC12 cell culture and treatment 
The rat pheochromocytoma PC 12 cell line has been reported as a model to study DAT 
trafficking (Loder and Melikian, 2003) and we used it to investigate the effects of 
amphetamine derivatives on DA transport (Chipana et al., 2008). For these reasons we 
considered these cells a suitable model for this study. PC 12 cells were routinely 
cultured in 92 mm dishes (Nunc) coated with collagen and maintained in DMEM 
supplemented with heat-inactivated 5% fetal bovine serum, 10% horse serum, 10 mM 
HEPES, 2 mM glutamine, 25 UI/ml penicillin and 25 g/ml streptomycin. Cells were 
cultured to semi-confluency in a humidified 5% CO2 atmosphere at 37 ºC, and medium 
was changed every 2-3 days. For splitting, cells were dislodged from the dish using a 
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pipette with medium, with a portion of these replated onto new culture dishes. Cells 
were used between passages 15 and 25. 
To ensure their proper differentiation, cells were mechanically dislodged and seeded 
(200 X 103 cells per well) onto collagen-coated 24-well plates (Nunc) in medium 
containing 50 ng/ml nerve growth factor (NGF, Upstate Biotechnology, Lake Placid, 
NY), 1% horse serum, 10 mM HEPES and 2% glutamine in DMEM. Under these 
conditions, the cells developed a neuronal phenotype with neurite outgrowth that was 
already apparent 24 h after seeding (Garcia-Rates et al. 2007). 
Treatments were performed 48 h after seeding in differentiation medium. MDPV was 
dissolved in DMEM and added to the corresponding wells in a volume of 10 µl to reach 
the desired final concentration. The concentration of MDPV used (0.1 µM) was chosen 
from preliminary experiments showing that higher concentrations required many 
washes to be removed, thus compromising the attachment of the cells. Previous reports 
stated that MDPV can reach peak concentrations of around 1 and 4 µM in plasma and 
striatum, respectively, after subcutaneous administration (Novellas et al. 2015). Control 
wells received 10 µl of DMEM. The plates were returned to the incubator for the 
desired time, until the binding experiment were performed. 
Binding of [3H]WIN 35428 to PC12 cells 
[3H]WIN 35428 binding was used to label membrane DAT in differentiated PC 12 cells. 
After incubation with MDPV, the medium was carefully removed and the cells were 
washed twice with 1 ml of warm Dulbecco’s phosphate buffered saline (PBS, 
Biological Industries Inc.). Then, 500 µl of [3H]WIN35428 (final radioligand 
concentration: 5 nM) diluted in 0.32 M sucrose-supplemented PBS was added to each 
well. A parallel set of wells also contained 30 µM bupropion to assess non-specific 
binding. The plates were placed on ice, and incubation was performed for 2 h at 4ºC. 
Binding was terminated by detaching the cells by pipetting and filtering through 
Whatman GF/B glass-fiber filters pre-soaked in 0.5% polyethileneimine, followed by 
three 1 ml washes of wells and filters with ice-cold buffer. The radioactivity retained in 
the filters was measured through liquid scintillation spectrometry. Each experiment was 
run in triplicate wells. 
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Animals and treatment 
The experimental protocols concerning the use of animals in this work were approved 
by the Animal Ethics Committee of the University of Barcelona under supervision of 
the Autonomous Government of Catalonia, following the guidelines of the European 
Communities Council (86/609/EEC).  Efforts were made to minimize suffering and 
reduce the number of animals used.  
Male adult Sprague-Dawley (SD) rats (aged 10-12 weeks and weighing 250-350 g; 
Harlan Ibérica, Barcelona, Spain) were used for synaptosome assays. They were housed 
at 22 ºC under a 12-h light/dark cycle with free access to food and water.  For in vitro 
incubations with the drugs, animals (2 rats per experiment) were anesthetized and 
sacrificed and synaptosomes were obtained. For ex-vivo experiments with synaptosomes 
originating from treated animals, MDPV (1.5 mg/kg) and cocaine (30 mg/kg) were 
dissolved in saline and administered subcunateously (s.c.) or intraperitoneally (i.p.), 
respectively in a volume of 1 ml/kg. Then, the animals were anesthetized and sacrificed 
and synaptosomes were obtained after 1, 3 or 16 h. The dose of MDPV used in this 
study (1.5 mg/kg) is equivalent to a dose of approximately 15 mg in humans (Reagan-
Shaw et al. 2008; Novellas et al. 2015) which is in the middle range of the doses most 
commonly used by consumers. The dose of cocaine of 30 mg/kg has been chosen on the 
basis that MDPV is more potent (10-30-fold) than cocaine (Baumann et al. 2013; 
Kolanos et al. 2013; Simmler et al. 2013), and the psychomotor stimulation induced by 
30 mg/kg of cocaine was not statistically different from that induced by 1.5 mg/kg of 
MDPV (see Figs. 6 and 7).  
The repeated administration procedure consisted in a daily administration of saline, 
MDPV or cocaine for 5 consecutive days, followed by 10 days of withdrawal and, one 
day after, a challenge of saline (1m/kg), MDPV (1.5 mg/kg, s.c.) or cocaine (30 mg/kg, 
i.p.) was injected. A similar procedure was reported by Gregg et al (2013) and our 
group, producing a robust psychomotor sensitization to MDPV and cocaine in mice 
(Buenrostro-Jáuregui et al., 2016). One set of animals received only the first dose to 
obtain the uptake values 1 h after the acute dose (Day 1, n = 4 for each treatment). Two 
other sets of rats were sacrificed 1 and 24 h after the fifth dose to obtain the results of 
Day 5 and Day 6 (n = 4 and 6 for each treatment group, respectively). Finally, another 
set of 6 animals per group was sacrificed 1 h after the challenge. 
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Obtention of striatal synaptosomes 
Striatal synaptosomes (P2 fraction) were obtained as described by Sandoval et al. 
(2001), with minor modifications. Rats were decapitated under isoflurane anesthesia, 
their brains rapidly removed and the striatum was dissected out on ice, weighed and 
placed in 20 volumes of cold homogenization buffer (5 mM Tris-HCl and 320 mM 
sucrose). Tissues were homogenized on ice using a borosilicate glass tube fitted with a 
motor-driven Teflon pestle and centrifuged twice to obtain the P2 fraction 
(synaptosomes). In the case of synaptosomes originating from treated rats, the pellet 
was resuspended in 5 ml of Tris-sucrose buffer and re-centrifuged 3 times, in order to 
wash out the residual drugs that could interfere with the experiments.  
Finally, the synaptosome fraction was resuspended in Hank’s Balanced Salt Solution 
(HBSS, Biological Industries, Inc.) supplemented with 5.5 mM glucose and 20 mM 
HEPES-sodium (HBSS/G/H, pH 7.4) for [3H]DA uptake experiments or in 0.1/0.32 M 
sodium phosphate/sucrose-buffer (pH 7.9) for [3H]WIN 35428 binding. The 
resuspension was done to reach a final protein concentration of approximately 0.1 
mg/ml. Protein concentration was determined using the BioRad Protein Reagent (Bio-
Rad Labs., Inc., Hercules, CA, USA) according to the manufacturer’s instructions and 
using bovine serum albumin as a standard.  
 [3H]DA uptake 
For in vitro treatment experiments, synaptosomes were obtained as described above and 
distributed in 1 ml aliquots in centrifuge tubes to perform the incubation with MDPV or 
cocaine in a shaking water bath at 37 ºC for 1 h. 10 µl of MDPV or cocaine solution or 
buffer was added to each tube to reach the desired final concentration (1 µM). After 
incubation, synaptosomes were centrifuged at 13000 x g for 20 min and washed three 
more times with 5 ml of Tris-sucrose buffer followed by centrifugation. The final 
pellets were resuspended in uptake buffer (HBSS/G/H buffer plus 10 µM pargyline and 
1 mM ascorbic acid). For experiments with tissue from treated rats, striatal 
synaptosomes were obtained as described above and, after the three washes, directly 
resuspended in uptake buffer. 
Reaction tubes consisted in 0.125 ml of uptake buffer, 0.1 ml of synaptosome 
suspension and 0.025 ml of [3H]DA added at the start of incubation. The remaining 
synaptosomes from each pellet were kept for further protein concentration assessment. 
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Tubes were warmed 5 min at 37 ºC before the addition of [3H]DA after which 
incubation was carried out for a further 5 min. Uptake reaction was stopped by rapid 
filtration as described for binding experiments. The radioactivity trapped on the filters 
was measured by liquid scintillation spectrometry. Non-specific uptake was determined 
at 4 ºC in parallel samples containing 100 µM cocaine. Specific DA uptake was 
calculated subtracting non-specific uptake values from those of total uptake (37 ºC). 
Each experiment was run in duplicate tubes. 
Specific DA uptake for each condition was normalized by dividing by the protein 
concentration and expressed as percentage of uptake with respect to control tubes. 
We could not perform reliable [3H]DA uptake in differentiated PC 12 cells with our 
means due to methodological issues (i.e., the need to perform repeated washes to 
remove free [3H]DA, leading to cell loss by detachment or, alternatively, to 
mechanically detach the cells and filtering which provokes indeterminate neurite and 
cell breaking with substrate leakage). 
Locomotor activity recording 
The locomotor responses induced by MDPV (1.5 mg/kg, s.c.) or cocaine (30 mg/kg, 
i.p.) were assessed in black Plexiglas open field arenas (l x w x h: 45 × 45 × 40 cm) 
under low-light conditions. Two days before testing, the animals were handled for 10 
min, administered saline (1 ml/kg) and placed in the arena for habituation for 30 min 
each day. On the test day, the rats were administered the assigned treatment and placed 
in the arenas and their horizontal travelling were video-monitored by a zenithal video-
camera coupled to a computer running a tracking software (Smart 3.0, Panlab, S.L.U., 
Barcelona, Spain) for 60 min. Total travelled distances were obtained and analyzed. 
Stereotypy scoring 
Stereotyped behaviors were scored by two observers blind to treatment condition using 
the method of Creese and Iversen (1974). Briefly, video recordings (60 min) were 
divided into 10-min segments. Behavior during the first min of each segment was rated 
on a 0–6 scale: 0 = asleep or lying down, 1 = predominantly slow locomotor activity 
with non-stereotyped rearing and sniffing, 2 = predominantly rapid locomotor activity 
with bursts of stereotyped rearing and sniffing, 3 = predominantly stereotyped rearing 
and sniffing with some locomotor activity, 4 = stereotyped rearing and sniffing 
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maintained in a small area of the enclosure, 5 = stereotyped behavior maintained in a 
small area with oral stereotypies (licking or gnawing), 6 = assumption of awkward or 
bizarre posture. A score between 0 and 2 is, generally, considered a normal behavior. 
Both raters were trained on the same set of sample videos and achieved an inter-rater 
reliability of at least 0.90 before scoring experimental recordings. The score for each rat 
and experimental day is the average sum of the scores obtained in each recording block 
by both observers. 
Data analysis 
One-way ANOVA followed by Tukey’s post-hoc test or Student’s t test was used to 
analyze data from the binding experiments with cells and synaptosomes. Paired data 
were applied when comparing KM and Vmax of control and MDPV from different 
experiments, as each one was performed with the same synaptosomal preparation. A 
two-way ANOVA was used to compare the effects of MDPV, cocaine and saline on DA 
uptake (treatment x time factors), as well as to compare the effects of the first dose with 
those of the challenge (treatment x dose factors) in the sensitization schedule. Finally, a 
two-way (day and treatment) ANOVA with repeated measures was used to analyze the 
temporal evolution of locomotion and stereotypies during the sensitization procedure. 
When the overall ANOVA yielded significant effects, Tukey’s post-hoc tests were 
applied for comparisons between groups. 
Results 
MDPV treatment increases [3H]WIN 35428 binding on the surface of 
differentiated PC12 cells 
After preliminary trials, we assessed the effect of the exposure to 0.1 µM MDPV on 
[3H]WIN 35428 binding to intact NGF-differentiated PC12 cells, as a measure of DAT 
present in the cell membrane. Incubation with the cathinone was performed for 30 min, 
1, 3 and 24 h. As can be seen in Fig. 1, a short (30 min-1 h) exposure to MDPV was 
able to increase superficial DAT expression by 120% compared to control (DMEM 
alone). This elevation was also evident at 3 hours, but was no longer different from 
control at 24 h (one-way ANOVA: F6,14 = 8,297, p < 0.001).  
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In vitro effects of MDPV and cocaine on [3H]DA uptake in striatal synaptosomes  
The effects observed on [3H]WIN 35428 binding in differentiated PC12 cells 
encouraged us to test if this increased binding was accompanied by increased function 
of DAT (increased DA uptake). Unfortunately, due to technical issues we could not 
perform uptake assays with these cells (see Methods). For this reason, we chose an 
alternative experimental model and investigated whether in vitro incubation of striatal 
synaptosomes with MDPV was able to modify DA uptake, as occurs with other 
amphetamine derivatives, and how such modification was influenced by substrate 
concentration. Due to its similar mechanism of action, we also sought to compare these 
effects with those of cocaine. For this reason, we performed kinetic [3H]DA uptake 
experiments with synaptosomes pre-incubated with either MDPV or  cocaine (both at 1 
µM) for 1 h and compared the values with those obtained from control (pre-incubated in 
the absence of drug) synaptosomes.  
For MDPV, significant increases in both KM (62%) and Vmax  (57%) were obtained, 
showing higher uptake values in the MDPV group as long the substrate concentration 
was raised (Fig. 2). Cocaine induced a more modest increase in Vmax (30%), without 
significantly modifying the KM value (Fig. 3). 
We also performed experiments measuring [3H]DA uptake after incubating striatal 
synaptosomes for 1 h with increasing concentrations of MDPV or cocaine. In this case, 
we chose a constant [3H]DA concentration of 0.2 µM because differences between 
control and drug-treated kinetic curves were more apparent from and above this 
concentration. One-way ANOVA for each drug reported statistically significant effects 
of drug treatment (MDPV: F5, 12 = 3.667, p < 0.05; cocaine: F5, 12 = 19.20, p < 0.0001). 
As depicted in Fig. 4A, MDPV produced a statistically significant increase in uptake at 
a concentration of 0.1 µM whereas the differences in uptake at the rest of concentrations 
did not reach statistical significance. On the other hand, cocaine started showing a 
tendency to up-regulate uptake at a concentration of 1 µM, which became statistically 
significant at concentrations of 10 and 50 µM (Fig 4B).  
Administration of a single dose of MDPV up-regulates DA uptake more potently 
and longer than cocaine. 
After the in vitro results, we investigated whether acute administration of MDPV to rats 
was able to similarly increase DA uptake. Accordingly, we treated rats with saline, 
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MDPV (1.5 mg/kg, s.c.) or cocaine (30 mg/kg, i.p.) and sacrificed them after 1, 3 and 
16 h (Fig. 5). Striatal synaptosomes were immediately obtained and washed and uptake 
of [3H]DA (0.2 µM) was performed. This substrate concentration was chosen after the 
in vitro experiments showing that the differences between groups were more apparent at 
higher [3H]DA concentrations.  
The two-way ANOVA of the results showed the existence of significant differences for 
treatment (F2, 27 = 60.09, p < 0.0001) and time (F2, 27 = 25.86, P< 0.0001), as well as a 
significant interaction between them (F4,27 = 13.30, p<0.0001). MDPV administration 
induced a significant increase in [3H]DA uptake (around 120 %, p<0.001) measured 1 h 
after administration which persisted until 3 h post-treatment.. Cocaine treatment also 
induced a significant, but smaller, increase than MDPV in [3H]DA uptake (around 75 
%, p<0.001) when assessed 1 h after administration, but it was no longer evident 3 h 
post-treatment. 
Effects of a repeated administration of MDPV or cocaine on DA uptake  
In view of the effects of an acute in vivo administration of MDPV (1.5 mg/kg), we 
investigated the consequences of its daily administration for 5 days, followed by 10 
days of withdrawal, on the changes in DA uptake induced by a challenge with the drug 
(1.5 mg/kg, s.c.). One set of rats was sacrificed 1 h after the first administration (acute, 
Day 1), and another set 1 h after the challenge dose (Challenge day). The same schedule 
was concomitantly carried out with cocaine (30 mg/kg) for comparison. Moreover, we 
sacrificed one set of rats 1 (Day 5) and 24 h (Day 6) after receiving the fifth dose of the 
assigned treatment in order to study how the DA uptake at these time points was 
affected. The results are depicted in Fig. 6.  
The two-way ANOVA showed significant effects of drug treatment (F2,48 = 95.00, 
p<0.0001) and time (F3,48 = 74.85, p<0.0001), as well as an interaction between these 
factors (F6,48 = 24.84, p<0.0001). The results and pot-hoc tests showed that there was an 
increase in DA uptake after the challenge in the striatum of rats which had received the 
repeated administration of MDPV and that this increase was higher than that produced 
by a single administration (p<0.05). As occurred with the acute dose, the effects of 
cocaine, although significant, were less than those of MDPV and, interestingly, the 
increase in DA uptake produced by the challenge with cocaine did not significantly 
differ from that of the acute dose (Day 1).  
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1 h after the fifth dose (Day 5), DA uptake was increased in the animals receiving drugs, 
especially those given MDPV, whose increase was significant with respect to saline. 
The increases, however, were not as high as those induced by the first doses (Day 1). 
Moreover, 24 h after the fifth dose (Day 6), the uptake levels were significantly reduced 
in the case of MDPV-treated rats, whereas those treated with cocaine did not show 
significant differences with respect to saline. 
Comparative effects of MDPV and cocaine in hyperlocomotion and stereotyped 
behavior during the repeated administration procedure 
Locomotor activity of rats was measured during the five days of administration and the 
challenge day in order to assess whether locomotor sensitization had also occurred. A 
two-way ANOVA with repeated measures revealed significant effects of treatment (F2,15 
= 38.21, p<0.0001) and day (F4,60 = 4.17, p<0.01), but no interaction between these 
variables. MDPV (1.5 mg/kg) and cocaine (30 mg/kg, which is considered a high dose) 
induced similar increases in locomotor activity (Fig. 7a). Interestingly, over the daily 
administration period, locomotor activity decreased in the case of MDPV or did not 
significantly change in the case of cocaine. Moreover, on the challenge day the two-way 
ANOVA revealed significant effects of treatment (F1,10 = 17.79, P<0.01) and day (F2,20 
= 27.49, p<0.0001) as well as an interaction between the two variables (F2,20 = 7.952 
p<0.01). The locomotor activity induced by both drugs was significantly less than that 
induced on the first day (Fig. 7b).  
However, we observed an increase in stereotypies over the administration days, 
including repetitive head weaving, sniffing and rearing, which could account for the 
reduction in ambulation. To explore this hypothesis, we re-analyzed the videos and 
scored the stereotyped behavior. The results are displayed in Figure 7 (Panels c and d), 
and the two-way ANOVA with repeated measures revealed a significant effect of 
treatment (F2,15 = 74.40, p<0.0001) and day (F4,60 = 43,87, p<0.0001) and a significant  
interaction between these factors (F8, 60 = 10.33, p<0.0001). The stereotypy score 
increased along the five days of treatment (Fig. 7c) and there was a sensitization of the 
stereotyped behavior on the challenge day for both drugs (p<0.001, Fig. 7d). Again, the 
stereotypy score on the challenge day for MDPV was higher than that of cocaine. The 
overall two-way repeated measures ANOVA comparing the stereotypies on Day 1 and 
after the challenge showed significant effects of treatment (F2, 15 = 91.33, p<0.0001) and 
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day (F1, 15 = 149.1, p<0.0001), as well as an interaction between these factors (F2, 15 = 
26.56, p<0.0001). 
Finally, to assess whether the increase in stereotypies was correlated with the decreased 
locomotion, we carried out the correlation analysis between stereotypy score and 
distance (shown in Fig. 8). As can be observed, there was a very significant negative 
correlation between stereotypy score and distance in the case of MDPV, while the 
analysis corresponding to cocaine did not reach statistical significance.  
Discussion 
In the present work, we studied the regulatory effects of MDPV on DAT density and 
function in vitro as well as DAT function after an acute administration and during a 
repeated schedule, followed by drug removal. As cited in the Introduction, apart from 
the effects produced when they reach the synapses, psychostimulants can rapidly induce 
either up- or down-regulation of DAT depending on their mechanism of action. MDPV 
(like cocaine) is a non-substrate DAT blocker, (Baumann et al. 2013; Simmler et al. 
2013), and therefore an up-regulation of this transporter would be expected. A small 
DA-releasing effect of MDPV at very low concentrations (1 nM) has also been reported 
(Shekar et al. 2017). However, the concentrations of MDPV reached in CNS after an 
average dosing are much higher (Novellas et al. 2015) and, therefore, a predominance of 
blockade is expected. Nevertheless, due to the higher affinity and potency on DAT 
when compared with cocaine, the study of such effects of MDPV are of great interest in 
order to increase the knowledge about this new drug and to predict possible side effects 
after its consumption. 
To start with, we tested the effects of MDPV exposition on surface DAT density 
([3H]WIN 35428 binding) in NGF-differentiated PC 12 cells. This cell line develops a 
phenotype of dopaminergic neurons upon differentiation and, therefore, is a good model 
to study dopaminergic drugs and DAT (Greene and Tischler 1976; Kittner et al. 1987; 
Chipana et al. 2008). We must point out that binding was carried out on intact plate-
attached cells, in order to avoid binding to intracellular forms of DAT which would 
have masked any change in the membrane population. Using this experimental model, 
we found that MDPV, at a concentration within those achieved in brain and plasma after 
recreational administration (Novellas et al. 2015), produces a rapid up-regulation of 
[3H]WIN 35428 binding sites which persists for at least 3 h. These results are in 
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agreement with those reported by other groups using cell lines transfected with hDAT 
and exposed to cocaine (Daws et al. 2002; Little et al. 2002). The decline in DAT after 
24 h incubation might have several explanations that require further investigation. One 
possibility could be the spontaneous degradation of MDPV or cell metabolism as PC 12 
have been reported to express several xenobiotic metabolizing cytochrome P450 
isoforms (Kashyap et al. 2011). The decrease in MDPV concentration may lead to a 
process of restorarion of DAT levels. 
Recently, Colon-Perez et al. (2018) reported a rapid internalization of fluorescence-
labeled DAT after 1 h exposure to MDPV (0.3 µM) in transfected HEK cells, whereas 
we found an increase in surface [3H]WIN 35428 binding. A possible explanation to this 
discrepancy is the fact that the model they used is not a neural derived cell line, does not 
constitutively express DAT, and does not contain dopamine or other monoamines. By 
contrast, PC 12 cells and striatal synaptosomes express DAT and might be equipped 
with all the machinery that may be involved in DAT trafficking and regulation in 
dopaminergic neurons under physiological conditions (i.e., secretory vesicles, dopamine 
receptors and dopamine itself) whereas the cell line used by Colon-Perez et al. might 
not. In fact, Little et al. (2002) used a neuronal cell line (N2A) for similar purposes and 
reported, as we do, an up-regulation of DAT upon incubation with cocaine, which is in 
line with our results and others’. 
The next step was to investigate whether this binding up-regulation was accompanied 
by increased DA uptake. For this reason, we moved to the in vitro model of striatal 
synaptosomes. This model had been successfully used by our group and others for 
measuring the effects of an acute exposure to METH and MDMA (Chipana et al. 2006; 
Escubedo et al. 2005; Hansen et al. 2002; Pubill et al. 2005; Sandoval et al. 2001). In 
these experiments, we studied the kinetics of DA uptake in striatal synaptosomes treated 
with buffer, MDPV or cocaine at the same concentration for 1 h. MDPV significantly 
increased Vmax, as cocaine, and increased KM, whereas cocaine did not significantly 
modify this parameter. The increase in Vmax is compatible with the increased [
3H]WIN 
35428 binding we found in PC12 cells treated with MDPV and that reported in hDAT-
transfected cell lines treated with cocaine (Little et al. 2002; Zahniser and Sorkin 2009) 
and indicates that there exists a rapid functional up-regulation of DAT upon acute 
exposition to MDPV and cocaine. The fact that KM remained unchanged after treatment 
with cocaine is in agreement with the results from Little et al. (2002) using transfected 
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cells. To our knowledge, this is the first time that such up-regulation is reported for 
MDPV and for cocaine in rat striatal synaptosomes. Moreover, the fact that these effects 
are produced in vitro in synaptosomes suggests that this up-regulation takes place 
rapidly, at the nerve terminals, without the need of increased gene translation or de novo 
protein synthesis. This is in line with the results reported using transfected cell lines, 
where no changes in DAT total protein or mRNA were found (Little et al. 2002; 
Zahniser and Sorkin 2009), suggesting a fast effect on DAT trafficking from endosomes 
to the plasma membrane by a mechanism that remains to be elucidated. The greater 
effects of MDPV compared with cocaine could be explained by its higher affinity for 
DAT (Baumann et al. 2013; Simmler et al. 2013). 
The relevance and relative impact of both increased KM and Vmax for DA uptake in the 
case of MDPV deserves further investigation. An interesting point is that significant 
increases in these two parameters have been reported in the nucleus accumbens of post-
mortem brains from schizophrenic patients (Haberland and Hetey 1987). In fact, the 
reported increase in KM was about two-fold, whereas what we found was about 50%. 
The changes in DAT function could be responsible, at least in part, of the psychiatric 
effects observed in some MDPV abusers (Schmoll et al. 2017). 
In addition, we assessed the effect of an in vitro incubation (1 h) with increasing 
concentrations of MDPV and cocaine on DA uptake. At a substrate concentration of 0.2 
µM, MDPV significantly increased uptake only at 0.1 µM while the concentrations of 
0.05 and 1 µM only reached statistical significance when compared with control using a 
Student’s t-test (data not shown). Interestingly, the uptake values at concentrations of 1 
µM and above were lower than at 0.1 µM, regardless increased Vmax was found thanks 
to using higher substrate concentrations. An explanation to this point could be the high 
affinity of MDPV for DAT, which is probably accompanied by a very slow dissociation 
rate. This slow dissociation makes necessary to perform repetitive washes to remove all 
drug residuals and reveal the transporter up-regulation. In fact, the MDPV 
concentrations of 10 and 50 µM initially produced uptake down-regulation when 
performing three washes (not shown), whereas performing one additional wash resulted 
in an uptake value higher than 100%. This phenomenon could also explain the increase 
in KM produced by MDPV, which suggests that, despite the up-regulation of 
transporters, a higher amount of substrate would be necessary to reach half the Vmax 
because the function of part of the DAT population might be impaired by residual 
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MDPV or previous exposition to high concentrations of drug. Conversely, the highest 
concentrations of cocaine produced an increase in uptake, with a steady maximum 
effect, which was lower than that of MDPV and in line with an increased Vmax without 
changes in KM. 
Given the in vitro effects of MDPV, we further investigated whether an in vivo acute 
dose of this drug induced such up-regulation and compared its effects with those of 
cocaine. In this case, we used doses of both drugs that produced similar psychomotor 
effects and measured uptake at a single concentration of [3H]DA, which according to 
the previous kinetic experiments showed the highest difference between groups. The up-
regulation of DA uptake also appeared in drug-treated animals, and the percentages of 
increase were higher than those found in vitro (Vmax), indicating that the in vivo 
conditions facilitate the observed effects. Again, MDPV showed a higher potency than 
cocaine at up-regulating DA uptake. Moreover, its effects lasted at least 3 h post-
administration, whereas the effects of cocaine were not significantly elevated at this 
time point. In both cases, the effect was reversible and no differences were found 16 h 
later. The longer persistence of MDPV effects could be explained by its long half-live in 
the brain, as significant levels of this drug can be found in striatum 3 h after 
administration (Novellas et al. 2015). Moreover, MDPV seems to have a slower 
dissociation from DAT, which implies the need to perform several washes of the 
preparation to remove residual drug, which can still be detected by HPLC-MS in 
synaptosomes even after tissue homogenization and centrifugation (data not shown). On 
the other hand, cocaine has been reported to disappear more rapidly from the brain, so 
that its concentration in rat brain is very low at 1 h after administration (Bowman et al. 
1999). This could explain why its effects on DAT are less persistent after a single 
administration. An aspect to consider is how long DAT is up-regulated once the drug 
concentration has declined in brain, because an increased number of DAT in the 
absence of blocker could produce a hypodopaminergic status that may lead to search for 
drug re-dosing. 
The next experiments focused on DA uptake after a repeated administration of these 
psychostimulants. Mash et al. (2002) reported a parallel increase in Bmax of [
3H]WIN 
35428 binding and Vmax for [
3H]DA uptake in post-mortem synaptosomes from cocaine 
abusers, indicating functional upregulation of DAT following chronic cocaine use. 
Another group (Samuvel et al. 2008) described that rats which self-administered cocaine 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
18 
 
followed by a 3-week abstinence showed a higher level of surface DAT and DA uptake 
in the striatum. 
No previous reports exist concerning the effects of MDPV on DAT density and 
function, so we investigated the function of DAT after a repeated administration regime 
with MDPV or cocaine, followed by a period of withdrawal and a challenge with the 
drug. Interestingly, we found a sensitization of the DA uptake up-regulation induced by 
MDPV, but not by cocaine. This indicates that MDPV, at the dose used, affects the 
population of DAT or its trafficking mechanisms differently, leading to increased up-
regulation by a re-exposure to the drug after a period of withdrawal. Further 
investigations are warranted in order to determine what mechanisms are involved in 
such effect. In line with these findings, when we assessed DA uptake 24 h after the fifth 
daily dose, we observed that uptake levels of cocaine-treated rats did not differ from 
controls, whereas those of the MDPV-treated group were significantly lower. This 
finding evidences again the differences between MDPV and cocaine. A recent 
publication by Colon-Perez et al. (2018) also reports DAT down-regulation 24 h after 
the administration of MDPV to rats. Moreover, we had previously reported a decrease 
in [3H]WIN 35428 binding in the striatum of mice that had received a repeated 
administration of MDPV (1.5 mg/kg) for 7 days after 21 days of withdrawal 
(preliminary results presented as a communication at the Neuroscience 2017 congress 
by Duart-Castells et al.). Although in the present work we did not measure DAT 
function after withdrawal, just before the challenge, these previous results suggest that 
DAT would be still down-regulated at this time point (10 days after). A reduced DAT 
population would also explain, at least in part, why the challenge with the same dose of 
MDPV increases the stereotypies, as the blockade of DA uptake would be higher, 
leading to a hyperdopaminergic status. Consequently, a higher uptake up-regulation 
would be expected as an attempt to restore normal DA synaptic levels. 
DAT down-regulation may be a homeostatic response once MDPV disappeared from 
the brain and left an increased population of free transporters that would dramatically 
reduce DA in the synapses if it was not normalized. The fact that DA uptake levels have 
returned to control values 16 h after an acute administration backs this argument. 
Moreover, 1 h after the fifth dose, DA uptake was significantly increased but to a lesser 
extent with respect to the first dose in MDPV rats, and closer to controls in the cocaine 
group. This suggests the development of a tolerance to the up-regulation of DAT that 
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may reflect a reduction in rapidly available DAT after the repeated administration. This 
could also account in some extent, to the subsequent reduction in DAT and to the 
sensitization of the homeostatic mechanism to respond to further exposures to the drug.  
Another interesting issue was the behavioral responses to this repeated administration 
regime. Behavioral sensitization to psychostimulants can be attributed not only to a 
direct pharmacological action of the drug but also to environmental conditions 
associated with the drug experience (Pierce and Kalivas 1997). It has been suggested 
that behavioral sensitization could be involved in the development and maintenance of 
drug addiction (Tzschentke and Schmidt 2000) through enhanced incentive salience 
(Robinson and Berridge 1993). When we measured locomotor activity every day after 
the drug administration we observed a progressive decrease in the locomotor response 
to the drug in the case of MDPV and a non-significant change in the case of cocaine. 
This response was also reflected on the challenge day, when both drug-treated groups 
showed a reduced locomotor activity after the drug administration when compared to 
that induced by the first dose, and very significant in the case of MDPV. These 
behaviors, however, were correlated with an increase in stereotypies, especially in the 
case of MDPV. Stereotypies appear after administration of a number of psychotropic 
drugs and become more apparent at higher doses in the case of psychostimulants, to an 
extent that they can preclude hyperlocomotion and mask it when measured as an 
indicator of psychostimulation (Creese and Iversen 1974; Pritchard et al. 2012). It has 
been suggested that stereotyped behavior is correlated with an imbalance between the 
medial prefrontal and sensorimotor circuits of the basal ganglia resulting in a loss of 
control of motor behavior (Aliane et al. 2009). Given the higher potency of MDPV, 
relatively low doses (if compared with cocaine) are able to produce stereotypies in rats 
and sensitization to these effects (Gregg et al. 2016). Similar effects had already been 
described for cocaine (Aliane et al. 2009; Souza et al. 2014). Our results are in line with 
those reported by Watterson et al. (2016), who used a 5-day daily or every 48 h 
administration of MDPV (1 or 5 mg/kg) followed by 5 days of withdrawal to assess 
motor sensitization. With this schedule, they only found motor sensitization to MDPV 
in the case of administering the drug every 48 h and at the dose of 1 mg/kg and 
attributed the lack of effect of 5 mg/kg to the strong stereotyped behavior that this dose 
induces, although they did not quantify stereotypies. In our case and theirs using the 
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daily administration of 1 mg/kg, sensitization to stereotypies might have developed 
more easily, thus precluding the locomotor sensitization. 
A reduced population of DAT at the time of challenge could account for an increased 
psychostimulant effect of MDPV leading to more intense stereotypies. Thus, the 
increased up-regulation of DAT with respect to Day 1 could obey an attempt to reduce 
the excess of DA in the synapses after the intense blockade by MDPV.  
In summary, we demonstrate here that acute exposure to MDPV induces rapid and 
reversible up-regulation of DAT function, probably as a response to the intense 
blockade exerted by the drug. This effect takes place at the nerve terminal, without the 
need of gene transcription or de novo protein synthesis, and is higher than that exerted 
by an equimolar (in vitro) or an equipotent (in vivo) dose of cocaine. Moreover, after 
repeated administration of MDPV, sensitization occurs to this effect. Further studies are 
needed to assess the impact of this regulation in the addictive properties of this drug, as 
well as to investigate the molecular mechanisms involved. 
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Figure captions 
Fig. 1 Effect of MDPV (0.1 µM) during different incubation times on [3H]WIN 35428 
binding to intact differentiated PC12 cells. Results are the means of two independent 
experiments carried out in triplicates and are expressed as the mean ± SEM of the 
percentage from the binding obtained in medium-treated cells (control).**p<0.01; 
***p<0.001 vs. control 
Fig. 2 Effect of pre-incubation with MDPV (1 µM) on [3H]DA uptake kinetics in rat 
striatal synaptosomes Panel a shows the values of Vmax, while panel b shows those of 
KM. Results are the means ± SEM from five experiments carried out on duplicates. 
Panel c depicts a representative experiment of such kinetics. **p<0.01 vs. control 
Fig. 3 Effect of pre-incubation with cocaine (1 µM) on [3H]DA uptake kinetics in rat 
striatal synaptosomes. Panel a shows the values of Vmax, while panel b shows those of 
KM. Results are the means ± SEM from five experiments carried out on duplicates. 
Panel c depicts a representative experiment of such kinetics. *p<0.05 vs. control 
Fig. 4 Effect of increasing MDPV (a) and cocaine (b) concentrations on [3H]DA uptake 
in rat striatal synaptosomes. Results are the means ± SEM from four experiments 
carried out on duplicates. *p<0.05; **p<0.01 vs. control (0 µM) 
Fig. 5 [3H]DA uptake in striatal synaptosomes from rats treated acutely with saline (1 
ml/kg, s.c.), MDPV (1.5 mg/kg, s.c.) or cocaine (30 mg/kg, i.p.) and sacrificed after 1, 3 
or 16 hours. Uptake values are normalized as percentage of control (saline group, 100 
%) and are the means ± SEM of those from four animals per group and time. ANOVA 
post-hoc comparisons: ***p<0.001 vs. saline at the same time point; ###p<0.001 vs. 
cocaine at the same time point 
Fig. 6 Effects of repeated daily administration of MDPV or cocaine on striatal DA 
uptake at different time points. Results are expressed as percentage of control (saline 
group, 100%) and are the mean ± SEM (n = 4 - 6 per group). Tukey’s post-hoc test: 
***p<0.001, **p<0.01 vs. saline at the same time point; ###p<0.001, ##p<0.01 vs. 
cocaine at the same time point; $$$p<0.001, $p<0.05 with respect to the same treatment 
group at Day 1; @@@p<0.001 with respect to the same treatment group at Day 5 
Fig. 7 a. Locomotor activity during daily administration of saline (1 ml/kg), MDPV (1.5 
mg/kg, s.c.) or cocaine (30 mg/kg, i.p.) to rats for 5 consecutive days. b. Locomotor 
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activity induced by a challenge with saline (1 ml/kg, s.c.), MDPV (1.5 mg/kg, s.c.) or 
cocaine (30 mg/kg, i.p.) after 10 days of withdrawal, compared with the distance 
recorded on Day 1. Panels c and d show the stereotypy scores assigned from the 
corresponding recordings to the data depicted in A and B, respectively. Data represent 
the mean ± SEM of the values from 6 rats per group. *p<0.05, **p<0.01, ***p<0.001 
vs. the corresponding value on Day 1. ##p<0.05 between the indicated groups 
Fig. 8 Correlation analyses between the means of the stereotypy score and the 
corresponding travelled distance during the consecutive 5 days of treatment with saline 
(1 ml/kg), MDPV (1.5 mg/kg, s.c.) or cocaine (30 mg/kg, i.p.) 
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